Amvuttra vutrisiran

The single most actionable signal: patients who switch to Amvuttra cite convenience (quarterly sub-Q vs. every-3-weeks IV) as the top driver, but the cost barrier ($476K list) is so visible online that it is co-occurring in the same breath as diagnosis, making financial-navigation speed the make-or-break adherence moment.

• Quarterly subcutaneous dosing is the dominant pull factor driving both new starts and switches from Onpattro (patisiran), as patients report the infusion burden of prior therapy as intolerable long-term.
• Sticker shock at Amvuttra's roughly $476,000 annual list price surfaces immediately at diagnosis and is the primary emotional barrier, even when out-of-pocket costs are ultimately covered through Alnylam Assist or Medicare Part B.
• Vitamin A level decline is the most discussed ongoing management concern, yet patients largely accept it as manageable once supplementation is explained clearly by their care team.
• A rising wave of ATTR-CM patients newly eligible after HELIOS-B data is entering the conversation with higher urgency around survival and hospitalization reduction, shifting the community tone from neuropathy-centric to cardiac-centric.